Arcus shares fell nearly 20% on October 21, 2026, closing at $19.10 after the biotechnology company released new clinical data for cancer drug candidate casdatifan and announced an underwritten public offering of common stock.
Key Takeaways
- RCUS closed at $19.10, down from the previous session’s $23.75, after trading between $19.04 and $24.49.
- The stock offering was announced, not reported as completed; its size and pricing were not supplied.
Table of Contents
- Arcus shares slide as clinical news coincides with financing plan
- Arcus valuation and earnings
- Financial indicators and insider transactions
Arcus shares slide as clinical news coincides with financing plan
The selloff followed two developments: an update on casdatifan, Arcus Biosciences’ HIF-2a inhibitor being evaluated for kidney cancer, and a planned equity financing.
Arcus, which trades on the New York Stock Exchange under RCUS, had a reported market capitalization of $2.43 billion. It remains a clinical-stage biopharmaceutical company with no approved drugs, operating mainly through collaborations and licensing agreements rather than product sales.
Arcus valuation and earnings
Arcus’s price-to-sales multiple was approximately 19.37, compared with its historical median of 12.17.
Reported earnings per share were negative $3.90 and the operating margin was negative 415.39%, making a conventional price-to-earnings comparison unhelpful. Arcus’s pipeline also includes domvanalimab, quemliclustat and zimberelimab.
Financial indicators and insider transactions
Arcus had a current ratio of 3.82 and a debt-to-equity ratio of 0.25.
Insider share sales totaled $13.6 million over the preceding 12 months, with no insider purchases.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
